Listed Companies To Benefit First From Biomedical Revitalization Plan
This article was originally published in PharmAsia News
Analysts predict the "Biomedical Revitalization Plan" to be released later this month, which will focus on vaccines, protein-based drugs, and monoclonal antibodies, will likely benefit listed biotech drug manufacturers first
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.